AzTrials
AzTrials

Anxiety DisordersPhase 3CBT vs RTW INCT01636791

CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care

A Phase 3 study testing Cognitive behavior therapy and Return to work in people with Anxiety Disorders and Major Depression, run by Karolinska Institutet at 1 site in Sweden.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: Common mental illness, such as anxiety disorders and depression, is the main cause for sick leave in Sweden. Cognitive behavior therapy (CBT) has been shown to be effective in alleviating target symptoms of these disorders, but its effect on sick leave rates has not been sufficiently addressed. Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
Cognitive behavior therapy and Return to work
Could I receive a placebo?
No, everyone receives an active treatment
How many people
211 participants
Where
1 siteSweden
Study dates
Sep 2012to Dec 2015
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Have been on sick leave (at least 50%) for at least 1 month and not more than 6 months
  • Have an anxiety disorder diagnosis (obsessive compulsive disorder, social phobia, panic disorder, generalized anxiety disorder, post-traumatic stress disorder, specific phobia), or/and major depression, or/and maladaptive stress reaction, or/and primary insomnia

Who cannot join

  • A lower score than 4 on the Clinician severity rating scale
  • A higher score than 6 on the Clinician severity rating scale

Trial locations and contacts

1 site in 1 country.

Sweden1 site
  • Karolinska Institutet and Gustavsberg primary care center

    Stockholm, Stockholm County, 13440

Other trials in Sweden

About this study

Official title: Cognitive Behavior Therapy Versus a Return to Work Intervention for Sick-listed Patients With Common Mental Illness in Primary Care: a Randomized Clinical Trial

Background: Common mental illness, such as anxiety disorders and depression, is the main cause for sick leave in Sweden. Cognitive behavior therapy (CBT) has been shown to be effective in alleviating target symptoms of these disorders, but its effect on sick leave rates has not been sufficiently addressed. The investigators have developed an intervention called return to work (RTW), which is based in cognitive behavioral theory, that has a primary aim of helping sick-listed patients with common mental illness return to work. This new treatment has not been evaluated in a randomized controlled trial.

Aims: The aim of this study is to investigate the effect of CBT and RTW for common mental illness in a randomized controlled trial conducted in primary care. Participants will be randomized to diagnosis specific CBT (n=70), RTW (n=70), or a combination of the two treatments (n=70). Main outcomes are days of sick leave and clinician severity rating of psychiatric symptoms. This study could contribute to new knowledge regarding how to best treat patients on sick leave with common mental illness.

Being tested
Cognitive behavior therapy, Return to work
Medical subject headings
Anxiety Disorders, Depressive Disorder, Major, Stress Disorders, Traumatic, Sleep Initiation and Maintenance Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cognitive behavior therapyBehavioural

    Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.

  • Return to workBehavioural

    Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.

Study groups in NCT01636791
Study groupRoleWhat they receive
Cognitive Behavior TherapyActive comparatorAs the trial will include several different common mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
Receives: Behavioral: Cognitive behavior therapy
Return to workExperimentalParticipants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
Receives: Behavioral: Return to work
CBT and Return to workExperimentalParticipants randomized to this arm will receive a combination of cognitive behavior therapy and the return to work treatment. This arm is included in the study as the clinically most relevant therapy, would the return to work treatment be effective in reducing sick leave, is a treatment were patients are provided support to return to work but also is clinically effective in reducing psychiatric symptoms.
Receives: Behavioral: Cognitive behavior therapy; Behavioral: Return to work

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sick leave

    Number of days on sick leave

    Measured: 1 year

  2. Clinician Severity Rating (CSR)

    Change in CSR at post-treatment, 26 week follow-up, and 52 week follow-up compared to baseline.

    Measured: Baseine, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up

Secondary outcomes (15)
  1. Montgomery-Åsberg Depression Rating Scale-Self-report (MADRS-S)

    Change in MADRS-S at post-treatment, 26 week follow-up, and 52 week follow-up

    Measured: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up

  2. Work ability index (WAI)

    Change in WAI at post-treatment, 26 week follow-up, 52 week follow-up

    Measured: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up

  3. Insomnia Severity Index (ISI)

    Change in ISI at post-treatment, 26 week follow-up, and 52 week follow-up

    Measured: Baseline, post-treatment (variable depending on disorder, 26 week follow-up, 52 week follow-up

  4. Health Anxiety Inventory (HAI)

    Change in HAI at post-treatment, 26 week follow-up, and 52 week follow-up

    Measured: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up

  5. Perceived Stress Scale (PSS)

    Change in PSS at post-treatment, 26 week follow-up, and 52 week follow-up

    Measured: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up

  6. Trimbos and Institute of Technology Cost Questionnaire for Psychiatry (TIC-P)

    Change in TIC-P at post-treatment, 26 week follow-up, and 52 week follow-up

    Measured: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up

  7. Quality of Life Inventory (QOLI)

    Change in QOLI at post-treatment, 26 week follow-up, and 52 week follow-up

    Measured: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up

  8. EuroQol-5 dimension (EQ5D)

    Change in EQ5D at post-treatment, 26 week follow-up, and 52 week follow-up

    Measured: Baseline, post-treatment (variable depending on disorder), 26 feel follow-up, 52 week follow-up

  9. Sheehan Disability Scales (SDS)

    Change in SDS at post-treatment, 26 week follow-up, and 52 week follow-up

    Measured: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up

  10. Self-rated health 5 (SRH-5)

    Change in SRH-5 at post-treatment, 26 week follow-up and 52 week follow-up

    Measured: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up

  11. Obsessive Compulsive Inventory-Revised (OCI-R)

    Change in OCI-R at post-treatment, 26 week follow-up, and 52 week follow-up. Disorder specific.

    Measured: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up

  12. Liebowitz Social Anxiety Scale Self-report (LSAS-SR)

    Change in LSAS-SR at post-treatment, 26 week follow-up, and 52 week follow-up. Disorder specific.

    Measured: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up

  13. Panic Disorder Severity Scale Self-rated (PDSS-SR)

    Change in PDSS-SR at post-treatment, 26 week follow-up, and 52 week follow-up. Disorder specific.

    Measured: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up

  14. Penn-State Worry Questionnaire (PSWQ)

    Change in PSWQ at post-treatment, 26 week follow-up, and 52 week follow-up. Disorder specific.

    Measured: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up

  15. Post Traumatic Stress Disorder Symptom Scale-Self report (PTSDSS)

    Change in PTSDSS at post-treatment, 26 week follow-up, and 52 week follow-up. Disorder specific.

    Measured: Baseline, post-treatment (variable depending on disorder), 26 week follow-up, 52 week follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jul 2012 (estimated)
  2. Study startSep 2012
  3. Primary completionDec 2015
  4. Study completionDec 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
211 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01636791
Sponsor's protocol ID
GVC CBT vs RTW
Acronym
CBT vs RTW I
Status last verified
Mar 2016
First submitted
5 Jul 2012
Last updated
3 Mar 2016
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Cognitive behavior therapy and Return to work in people with Anxiety Disorders and Major Depression, run by Karolinska Institutet at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Mar 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sick leave (time frame: 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2016.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in